Dataset related to article "Nonmyeloablative Conditioning Regimen before T Cell Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide for Advanced Hodgkin and Non-Hodgkin Lymphomas"

This record contains data related to article Nonmyeloablative Conditioning Regimen before T Cell Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide for Advanced Hodgkin and Non-Hodgkin Lymphomas Allogeneic hematopoietic stem cell transplantation (allo-SCT) is a valid option in patients with refractory lymphomas.<br> HLA haploidentical stem cell transplantation (haplo-SCT) expanded the accessibility to allogeneic hematopoietic<br> cell transplantation. The aims of study were to retrospectively assess the toxicity and efficacy of haplo-SCT<br> using nonmyeloablative conditioning in patients with advanced lymphoma. In total, 147 patients with advanced<br> lymphoma at 2 partner institutions were included. Patients received a uniform nonmyeloablative conditioning<br> regimen and graft-versus-host disease (GVHD) prophylaxis. The primary endpoints were progression-free survival<br> (PFS), overall survival (OS), GVHD, nonrelapse mortality, and GVHD, relapse-free survival (GRFS). Median follow-<br> up was 39 months (range, 6 to 114 months). The median age was 46 years (range, 19 to 71 years). Sixty-five<br> percent of patients were in complete remission (CR) at transplantation. Cumulative incidence of grade II to IV<br> acute GVHD was 30% (95% confidence interval [Cl], 23% to 38%). Two-year cumulative incidence of all grades of<br> chronic GVHD was 13% (95% CI, 8% to 20%). Two-year cumulative incidence of disease relapse was 19% (95% CI,<br> 14% to 27%), with a higher incidence in patients not being in CR at allo-HCT (CR versus not CR: 12% versus 33%,<br> P = .006). Two-year PFS, OS, and GRFS were 66% (95% CI, 59-75), 73% (95% CI, 66-81), and 56% (95% CI, 48-65),<br> respectively. Haplo-SCT with post-transplantation cyclophosphamide may be considered a valid option for<br> patients with aggressive lymphoma and deserves further evaluation.